24 min

Research Recap | The Growing Appetite for Obesity Drugs Making Sense

    • Business

The market for GLP-1s — also commonly known as obesity drugs — is projected to exceed $100 bn globally by 2030. Why are these drugs growing in popularity, and could they lead to a paradigm shift in health care? Elif Korkmaz, who covers Health Care Specialist Sales, sits down with Chris Schott, Senior Analyst covering U.S. Diversified Biopharma, and Richard Vosser, Head of European Pharma & Biotech, to discuss the latest developments in this space.
This episode was recorded on Wednesday, November 29th.
This communication is provided for information purposes only. Please read JP Morgan research reports related to its contents for more information including important disclosures.
Copyright 2023 JP Morgan Chase & Co. All rights reserved.

The market for GLP-1s — also commonly known as obesity drugs — is projected to exceed $100 bn globally by 2030. Why are these drugs growing in popularity, and could they lead to a paradigm shift in health care? Elif Korkmaz, who covers Health Care Specialist Sales, sits down with Chris Schott, Senior Analyst covering U.S. Diversified Biopharma, and Richard Vosser, Head of European Pharma & Biotech, to discuss the latest developments in this space.
This episode was recorded on Wednesday, November 29th.
This communication is provided for information purposes only. Please read JP Morgan research reports related to its contents for more information including important disclosures.
Copyright 2023 JP Morgan Chase & Co. All rights reserved.

24 min

Top Podcasts In Business

Money Stuff: The Podcast
Bloomberg
REAL AF with Andy Frisella
Andy Frisella #100to0
Money Rehab with Nicole Lapin
Money News Network
The Ramsey Show
Ramsey Network
In Good Company with Nicolai Tangen
Norges Bank Investment Management
Habits and Hustle
Jen Cohen and Habit Nest